GSK Pharma Q4: Net Profit Declines 89%, Declares Rs 32/Share Dividend

Large cap Pharmaceuticals sector company Glaxosmithkline Pharmaceuticals Ltd on Wednesday reported a sharp 89.1% YoY dip in its net profit at Rs 133.4 crore for the quarter ended March 31, 2023. The company declared its net profit at Rs 1219 crore for the corresponding quarter last year. Board of directors of Glaxosmithkline Pharmaceuticals Ltd recommended a dividend of Rs 32/- per equity share for the year ended March 31, 2023. Check details below:

Glaxosmithkline Pharmaceuticals Announces Dividend: According to the BSE filing of the company, "The Board has recommended a dividend of Rs. 32/- per equity share on face value of Rs 10 each for the year ended 31 st March 2023, subject to approval of members at 98th Annual General Meeting."

Glaxosmithkline Pharmaceuticals Q4: Glaxosmithkline declared that for the March quarter its total revenue stood at Rs 787.5 crore, down 2.7% as against Rs 809.6 crore reported in the corresponding quarter of last fiscal. Meanwhile, at the operating level, EBITDA fell 3% to Rs 169.7 crore in the fourth quarter of this fiscal as against Rs 175.2 crore announced in the corresponding period in the previous year.

For FY23, revenue declared at Rs 3,216 crore and profit before tax (PBT) from continuing operations (before exceptional items) surged 9% to Rs 833 crore.

Bhushan Akshikar, Managing Director of GlaxoSmithKline Pharmaceuticals said, "With the launch of our global blockbuster Shingrix, we expect to address an unmet preventive health need and gain momentum for our vaccines business."

Glaxosmithkline Pharmaceuticals Stock Performance & Return: Last trading share price of Glaxosmithkline is Rs 1291.65 apiece with intraday gain of 0.11% on BSE as of May 17, 2023. Glaxosmithkline share 52-week high is Rs 1565.55 apiece and 52-week low price is Rs 1228.00 apiece, respectively. Market capitalisation of 21,881.33 crore. Glaxosmithkline shares jumped 4% in last 3-months, declined 15% in last 1-year, fell 7% in last 3-years, gave return of 7% in last 5-years.